Greenland Mines Ltd
Greenland Mines Ltd, formerly known as Klotho Neurosciences, Inc., trades on Nasdaq under the symbols GRML and GRMLW. The company operates at www.greenlandmines.com and develops essential medicines for treating chronic diseases including cancer, cardiovascular disorders, and neurodegenerative conditions. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Greenland Mines Ltd does
In the company’s own words
Greenland Mines Ltd, formerly known as Klotho Neurosciences, Inc., trades on Nasdaq under the symbols GRML and GRMLW. The company operates at www.greenlandmines.com and develops essential medicines for treating chronic diseases including cancer, cardiovascular disorders, and neurodegenerative conditions.
The company maintains three primary business segments. Its gene therapy platform focuses on developing treatments using a proprietary, patented approach centered on the Klotho protein, specifically the secreted-Klotho variant (s-KL), to address neurodegenerative diseases and age-related disorders. Lead candidates include KLTO-101 for Alzheimer's disease treatment and KLTO-202 for amyotrophic lateral sclerosis (ALS). The company has licensed exclusive worldwide rights to this technology from the Universitat Autònoma de Barcelona and related institutions, with issued patents in the United States, Europe, China, and Hong Kong, and pending applications in Canada and Japan.
The biosimilar biologics platform develops off-patent biosimilar antibodies targeting cancer treatment. Licensed from Reliance Life Sciences, this segment includes development programs for rituximab, trastuzumab, bevacizumab, and cetuximab biosimilars for markets in North America, Europe, and Israel.
The generic drug portfolio comprises market-approved anti-cancer medications acquired in September 2022, including drugs used in FOLFOX and FOLFIRI multi-drug regimens for metastatic colorectal and gastric cancers, as well as medications for metastatic lung cancer treatment.
In March 2026, the company completed an acquisition of Greenland Mines Corp., significantly expanding operations into the development and mining of critical and precious minerals, representing a strategic diversification beyond its pharmaceutical focus.
The company's research and development efforts emphasize advancing cell and gene therapy candidates through preclinical and clinical development stages, with plans to pursue regulatory approvals in major markets including the United States, Canada, Europe, China, and other viable jurisdictions. The company operates as a smaller reporting company and is not a well-known seasoned issuer.
Company details
- Sector
- Healthcare
- Industry
- Biological Products
- Headquarters
- OMAHA, NE
- Fiscal year end
- December
- CIK
- 1907223
- SIC
- 2836
Financial performance, year by year
Fiscal 2022–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Greenland Mines Ltd — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Greenland Mines Ltd’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Greenland Mines Ltd and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Greenland Mines Ltd's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Greenland Mines Ltd's last four quarterly filings that the numbers alone won't show?”